Antibody-Drug Conjugates Using Stable Non-Disulfide Linkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates for cancer treatment, particularly those using disulfide linkers, exhibit reduced potency and safety issues due to non-specific drug release and toxicity, necessitating the development of more targeted and stable delivery methods for maytansinoid drugs to cancer cells.
Innovation Solution
The use of stable, non-disulfide linkers to attach maytansinoid drug moieties to antibodies, ensuring controlled drug release only upon cellular uptake, thereby enhancing in vitro potency and in vivo efficacy while minimizing systemic toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If disulfide linkers are used to attach maytansinoid drugs to antibodies, then the conjugate can be formed, but the conjugate exhibits reduced potency and causes systemic toxicity due to non-specific drug release
Solution Approach 1:
The patent changes the chemical parameter of the linker from disulfide-based to non-disulfide stable linkers (such as maleimide, SMCC, or other covalent linkers). This parameter change results in conjugates that maintain structural integrity in circulation, preventing non-specific drug release and associated toxicity, while still enabling controlled drug release upon cellular uptake through alternative mechanisms such as proteolytic cleavage or reduced stability in the cellular environment.
2Reliability
If disulfide linkers are used in antibody-drug conjugates, then conjugation is achieved, but in vitro potency is reduced due to non-specific drug release
Solution Approach 1:
The patent modifies the linker chemistry parameter from disulfide to non-disulfide stable linkers that resist cleavage under extracellular conditions. This ensures the conjugate maintains its intact structure during circulation and tissue penetration, delivering the drug precisely where needed and thereby restoring high in vitro potency by eliminating off-target effects.
3Reliability
If stable non-disulfide linkers are used to attach maytansinoid drugs to antibodies, then controlled drug release is achieved, but the complexity of conjugate formation increases
Solution Approach 1:
The patent employs intermediary linker molecules (such as maleimide-containing linkers, SMCC, or other bifunctional linkers) that facilitate the conjugation process. These intermediaries react with both the antibody (via functional groups like amines or carboxyls) and the maytansinoid drug, creating a stable conjugate. While the chemistry is more sophisticated than simple disulfide linkers, the use of standardized intermediary linkers actually streamlines the conjugation process and improves reproducibility.
Data Source
AI summary
The present invention relates to antibody-drug conjugate compounds of Formula I:Ab-(L-D)p Iwhere one or more maytansinoid drug moieties (D) are covalently linked by L to an antibody (Ab) which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be used in methods of diagnosis or treatment of cancer, and other diseases and disorders.